Latest
March 19, 2019
Clarivate Analytics recently released its Cortellis Drugs to Watch 2019 report, which analyzed seven drugs set to enter the market this year and achieve "blockbuster" status ($1 billion in annual sales) by 2023.
Blockbuster drugs face great market potential and are often a “make or break” for some pharmaceutical companies, especially those with a limited drug pipeline or small portfolio. As with any new product, they can face an onslaught of competitive challenges in the market, but the one competitor that must not be forgotten is the threat posed by counterfeiters.
The pharma industry is one of the most regulated sectors in the...
Read More




